| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| 250mg | |||
| Other Sizes |
| Targets |
Camelliaside A has radical scavenging and enzyme inhibitory activities. It scavenges superoxide radicals in cell-free assays. The compound also demonstrates antioxidant, anti-inflammatory, antimicrobial, and hepatoprotective activities. Further research is needed to identify specific molecular targets.
|
|---|---|
| ln Vitro |
Camelliaside A exhibits significant radical scavenging activity, scavenging superoxide radicals in cell-free assays. The compound demonstrates antioxidant, anti-inflammatory, antimicrobial, and hepatoprotective activities. It is a flavonol triglycoside isolated from Camellia sinensis seeds.
|
| ln Vivo |
In vivo, camelliaside A has been studied for its hepatoprotective and anti-inflammatory activities. The compound's antioxidant properties contribute to its potential therapeutic effects. Further in vivo studies are needed to fully characterize its therapeutic potential.
|
| Enzyme Assay |
In vitro enzyme assays for camelliaside A involve measuring its radical scavenging activity and enzyme inhibitory effects. The compound's ability to scavenge superoxide radicals is assessed using cell-free assays. Enzyme inhibition is measured using appropriate substrates and various concentrations of camelliaside A.
|
| Cell Assay |
In vitro cellular assays for camelliaside A involve treating cells with the compound and measuring antioxidant activity, inflammatory responses, or cell viability. Cells are treated with various concentrations of camelliaside A, and reactive oxygen species levels, cytokine production, or cell viability are measured. The compound demonstrates antioxidant, anti-inflammatory, and antimicrobial activities.
|
| Animal Protocol |
In vivo animal studies for camelliaside A typically involve administration to rodent models of liver injury, inflammation, or infection. The compound's hepatoprotective and anti-inflammatory activities are assessed by measuring liver enzymes, inflammatory markers, and tissue histology.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for camelliaside A is limited. The compound has a molecular weight of 756.66 and a molecular formula of C33H40O20. It has a density of 1.79±0.1 g/cm³ (20°C, 760 torr) and is almost insoluble in water (0.055 g/L at 25°C). Further pharmacokinetic studies are needed.
|
| Toxicity/Toxicokinetics |
Preclinical toxicity studies of camelliaside A are limited. The compound demonstrates antioxidant, anti-inflammatory, antimicrobial, and hepatoprotective activities, suggesting a favorable safety profile. Comprehensive toxicological evaluation is needed before clinical development.
|
| References | |
| Additional Infomation |
Reports have indicated that the tea plant (Camellia sinensis) contains tea plant glycoside A, and relevant data is available for reference.
Camelliaside A is a flavonol triglycoside isolated from Camellia sinensis seeds with antioxidant, anti-inflammatory, antimicrobial, and hepatoprotective activities. It is a kaempferol derivative with the structure kaempferol 3-O-(2-O-beta-D-galactopyranosyl-6-O-alpha-L-rhamnopyranosyl)-beta-D-glucopyranoside. The compound has a molecular formula of C33H40O20 and a molecular weight of 756.66 and scavenges superoxide radicals in cell-free assays. |
| Molecular Formula |
C33H40O20
|
|---|---|
| Molecular Weight |
756.66
|
| Exact Mass |
756.211
|
| CAS # |
135095-52-2
|
| PubChem CID |
25115189
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.79±0.1 g/cm3
|
| Boiling Point |
1094.1±65.0 °C at 760 mmHg
|
| Flash Point |
344.1±27.8 °C
|
| Vapour Pressure |
0.0±0.3 mmHg at 25°C
|
| Index of Refraction |
1.743
|
| LogP |
0.03
|
| Hydrogen Bond Donor Count |
12
|
| Hydrogen Bond Acceptor Count |
20
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
53
|
| Complexity |
1280
|
| Defined Atom Stereocenter Count |
15
|
| SMILES |
C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC3=C(OC4=CC(=CC(=C4C3=O)O)O)C5=CC=C(C=C5)O)O[C@H]6[C@@H]([C@H]([C@H]([C@H](O6)CO)O)O)O)O)O)O)O)O
|
| InChi Key |
VNLOLXSJMINBIS-XWAGUSETSA-N
|
| InChi Code |
InChI=1S/C33H40O20/c1-10-19(38)23(42)26(45)31(48-10)47-9-17-21(40)25(44)30(53-32-27(46)24(43)20(39)16(8-34)50-32)33(51-17)52-29-22(41)18-14(37)6-13(36)7-15(18)49-28(29)11-2-4-12(35)5-3-11/h2-7,10,16-17,19-21,23-27,30-40,42-46H,8-9H2,1H3/t10-,16+,17+,19-,20-,21+,23+,24-,25-,26+,27+,30+,31+,32-,33-/m0/s1
|
| Chemical Name |
3-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-3-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxy-5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one
|
| Synonyms |
Kaempferol 3-O-(2-O-galactopyranosyl-6-O-rhamnopyranosyl)glucopyranoside; Camelliaside A
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~132.16 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.30 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (3.30 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (3.30 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3216 mL | 6.6080 mL | 13.2160 mL | |
| 5 mM | 0.2643 mL | 1.3216 mL | 2.6432 mL | |
| 10 mM | 0.1322 mL | 0.6608 mL | 1.3216 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
